PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20226009-5	2010	We also established that rosiglitazone (a PPARgamma agonist) elevated MKP-1 expression level in NSCLC cells and inhibited tumour metastasis.	Rosiglitazone	25-38	dual specificity phosphatase 1	Mus musculus	70-75	
20226009-8	2010	MKP-1 modulating agents such as rosiglitazone and triptolide were used to demonstrate MKP-1"s role in tumorigenesis.	Rosiglitazone	32-45	dual specificity phosphatase 1	Mus musculus	0-5	
20226009-8	2010	MKP-1 modulating agents such as rosiglitazone and triptolide were used to demonstrate MKP-1"s role in tumorigenesis.	Rosiglitazone	32-45	dual specificity phosphatase 1	Mus musculus	86-91	
20226009-12	2010	Pharmacologically, rosiglitazone, a peroxisome proliferator activated receptor-gamma (PPARgamma) agonist appeared to induce MKP-1 expression while reduce MMP-2 and CXCR4 expression.	Rosiglitazone	19-32	dual specificity phosphatase 1	Mus musculus	124-129	
20226009-15	2010	Cells pre-treated with triptolide (a MKP-1 inhibitor), reversed rosiglitazone-mediated cell invasion and migration.	Rosiglitazone	64-77	dual specificity phosphatase 1	Mus musculus	37-42